Cullinan Therapeutics, Inc. reported total assets of $322.6 million as of September 30, 2026, a decrease from $448.4 million at the end of 2025, primarily driven by a reduction in short-term and long-term investments. The company maintains a strong liquidity position with $289.6 million in cash, cash equivalents, and short-term investments to fund its clinical-stage product candidates. Total liabilities remained relatively stable at $41.3 million.
Cullinan Therapeutics reported third quarter 2026 financial results and provided a corporate update on its T cell engager portfolio. The company ended the quarter with $313.8 million in cash and investments, providing a projected cash runway into 2029. Key upcoming milestones include data readouts for CLN-978 in autoimmune indications and the completion of the zipalertinib NDA submission in November.
Term
Q3 2026
“Our progress this quarter underscores our ability to execute across a differentiated and rapidly advancing portfolio. In addition to the recent clinical success and regulatory progress of zipalertinib, we have advanced velinotamig into a global study in autoimmune cytopenias and initiated a potentially registrational Phase 2 study of CLN-049 in relapsed and refractory AML.”
Nadim Ahmed, President and CEO of Cullinan Therapeutics
“Looking ahead, we remain focused on strengthening our leadership position in the T cell engager space. This December, we will share an update for CLN-978 across our ongoing clinical trials in three autoimmune indications and will share updated data for CLN-049 at the ASH Annual Meeting. With multiple upcoming clinical catalysts and regulatory milestones, coupled with our strong balance sheet, we are well positioned to translate this momentum into meaningful progress for patients and long-term value for shareholders.”
Nadim Ahmed, President and CEO of Cullinan Therapeutics
Cullinan Therapeutics announced positive interim Phase 1b/2a clinical data for velinotamig in patients with refractory systemic lupus erythematosus (SLE). The data showed that 8 of 9 evaluable patients achieved clinically meaningful reductions in disease activity, with 4 of 7 patients with high baseline proteinuria achieving a complete renal response. The therapy demonstrated a favorable safety profile with no Grade 3 or higher cytokine release syndrome or neurotoxicity.
Cullinan Therapeutics CSO Jennifer Michaelson Sells $49.4K of Stock
Jennifer Michaelson, CSO, sold 4,000 shares of Cullinan Therapeutics, Inc. at $12.36 a share, worth $49.4K in total on Nov 5, 2026. Shares held after the trade: 158,649 (-2.5%).
Cullinan Therapeutics released updated Phase 1 dose escalation data for CLN-049 in patients with relapsed or refractory AML and MDS, showing an ORR of 45% at the 12 µg/kg dose level. The company also announced that these results, along with data for velinotamig, will be presented at the 68th ASH Annual Meeting in December 2026. The data demonstrated that a two step-up dosing regimen improved safety by reducing the incidence and severity of cytokine release syndrome.
Cullinan Therapeutics has initiated a rolling New Drug Application (NDA) submission to the FDA for zipalertinib in combination with chemotherapy for first-line treatment of NSCLC with EGFR exon 20 insertion mutations. The submission is being conducted under the FDA's Real-Time Oncology Review (RTOR) program and is supported by positive Phase 3 REZILIENT3 trial data. Completion of the submission is expected by year-end 2026, potentially triggering a $100 million milestone payment from partner Taiho upon approval.
Cullinan Therapeutics outlined its anticipated pipeline milestones for the fourth quarter of 2026, including data readouts for its T cell engager programs CLN-978, velinotamig, and CLN-049. The company plans to share multi-dose regimen data for CLN-978 across SLE, RA, and Sjögren’s disease in December, and velinotamig data at the ACR Convergence conference in November.